0001140361-18-032008.txt : 20180710
0001140361-18-032008.hdr.sgml : 20180710
20180710131155
ACCESSION NUMBER: 0001140361-18-032008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180706
FILED AS OF DATE: 20180710
DATE AS OF CHANGE: 20180710
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sofia Michael J.
CENTRAL INDEX KEY: 0001635324
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34949
FILM NUMBER: 18946570
MAIL ADDRESS:
STREET 1: C/O ONCORE BIOPHARMA, INC.
STREET 2: 3805 OLD EASTON ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arbutus Biopharma Corp
CENTRAL INDEX KEY: 0001447028
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 980597776
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100-8900 GLENLYON PARKWAY
CITY: BURNABY
STATE: A1
ZIP: V5J 5J8
BUSINESS PHONE: 604-419-3200
MAIL ADDRESS:
STREET 1: 100-8900 GLENLYON PARKWAY
CITY: BURNABY
STATE: A1
ZIP: V5J 5J8
FORMER COMPANY:
FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp
DATE OF NAME CHANGE: 20110607
FORMER COMPANY:
FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20081003
4
1
doc1.xml
FORM 4
X0306
4
2018-07-06
0
0001447028
Arbutus Biopharma Corp
ABUS
0001635324
Sofia Michael J.
C/O ARBUTUS BIOPHARMA CORP.
SUITE 100, 8900 GLENLYON PARKWAY
BURNABY
A1
V5J 5J8
BRITISH COLUMBIA, CANADA
0
1
0
0
Chief Scientific Officer
Common Shares
2018-07-06
4
S
0
10000
8.45
D
1523403
D
Common Shares
2018-07-09
4
S
0
10000
8.906
D
1513403
D
Common Shares
171412
I
Held by Irrevocable Deed of Trust of Michael J. Sofia dated December 22, 2014 (the "Trust")
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.50 to $9.35, inclusive. The reporting person undertakes to provide to Arbutus Biopharma Corp., any security holder of Arbutus Biopharma Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the rages set forth in this footnote.
/s/ David C. Hastings, as attorney-in-fact for Michael J. Sofia
2018-07-10